This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Corneal crosslinking in pellucid marginal degeneration

Corneal crosslinking in pellucid marginal degeneration
Reviewed by Su Young

1 April 2020 | Su Young | EYE - Cornea, EYE - General
Share This

Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the 4 to 8 o’clock position. Compared to other corneal thinning conditions like keratoconus, corneal steepening in PMD occurs more inferiorly and closer to the limbus. Progression of PMD is important because keratoplasty in PMD is associated with significant comorbidity (e.g. decentered grafts closer to limbus confer a greater risk of vascularisation, suture erosion and rejection). All of the studies included additional treatments that were used with CXL: photorefractive keratectomy (PRK), phototherapeutic keratectomy (PTK) and intrastromal corneal ring segment (ICRS). CXL was shown to halt disease progression and stabilise / improve vision in all studies. Four studies included follow-up duration >1 year. Combined CXL and laser vision correction demonstrated a greater improvement in uncorrected distance visual acuity (UDVA) vs. CXL alone. In the studies, CXL was performed immediately after surface ablation, theoretically combining benefits of both treatments. None of the studies reported any complications, however rare but serious potential complications can occur and should be noted. The authors concluded that CXL seems to be safe and effective in the management of PMD, but existing literature is limited, with short-term follow-up and the retrospective nature of most studies. There is a lack of evidence supporting efficacy and stability of CXL in PMD, and well-controlled prospective studies with long-term follow-up are necessary.

Corneal cross-linking: an effective treatment option for pellucid marginal degeneration.
Yong J, Hatch KM.
SEMINARS IN OPHTHALMOLOGY
2019;34(7-8):512-7.
Share This
Su Young
CONTRIBUTOR
Su Young

Tennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency